Subscribe To
PEN / Penumbra: Appeal Improves, Just Not Appealing Yet
PEN News
By Zacks Investment Research
November 3, 2023
Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase
Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends. more_horizontal
By Seeking Alpha
November 2, 2023
Penumbra, Inc. (PEN) Q3 2023 Earnings Call Transcript
Penumbra, Inc. (PEN) Q3 2023 Earnings Call Transcript more_horizontal
By Seeking Alpha
October 16, 2023
Penumbra: Appeal Improves, Just Not Appealing Yet
Penumbra's shares have nearly been cut in half after doubling in a six-month period, making investors cautious. The company has shown continued growth more_horizontal
By Zacks Investment Research
October 12, 2023
Here's Why You Should Hold on to Penumbra (PEN) Stock for Now
Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses. more_horizontal
By Zacks Investment Research
September 22, 2023
Bull of the Day: Penumbra (PEN)
Penumbra ( PEN ) is the $10 billion innovator of neurovascular treatments for stroke using catheter aspiration technologies. After a solid beat-and-ra more_horizontal
By Zacks Investment Research
September 5, 2023
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank. more_horizontal
By Zacks Investment Research
August 2, 2023
Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised
Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the seco more_horizontal
By Seeking Alpha
August 1, 2023
Penumbra, Inc. (PEN) Q2 2023 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Jee Hamlyn-Harris - IR Adam Elsesser - Chai more_horizontal